ADNTRO
Pioneer in Genome Exploration and Interpretation

In a world driven by an insatiable curiosity about the future, the healthcare sector stands at the forefront of innovation. Modern medical science, empowered by state-of-the-art genetic tools, is on the verge of unveiling the mysteries concealed within our DNA, profoundly influencing the trajectory of health and well-being. Amid this rapidly evolving landscape, ADNTRO emerges as an avant-garde force. Harnessing the formidable capabilities of Artificial Intelligence (AI) and drawing inspiration from different fields, mathematics being at the core of their innovation, and most recently, by applying LLMs solutions as an innovative tool, enabling direct and interactive dialogue with one's genetic code – Like a chatGPT for your genetic code.

This groundbreaking innovation opens the door to exploring genetic predispositions, uncovering inherent biases, and gaining profound insights into susceptibility or immunity to specific diseases. Although DNA sequencing has become increasingly accessible, the true challenge lies in decoding this treasure trove of genetic data. ADNTRO's pioneering platform, driven by AI and advanced algorithms, adeptly unravels the mysteries concealed within one's DNA.

"We employ advanced genetic data analysis to swiftly and effectively scrutinize DNA information from various segments of the genome. Utilizing specialized tools to prioritize genetic variations and algorithms to comprehend how these variations impact an individual's health in two areas, the DTC area based on genotyping and Whole Exome and Whole Genome for reports conducive to clinical decision-making," says Guillermo Perez-Solero, CEO of ADNTRO Genetics.

In the realm of Immunogenetics, ADNTRO has developed an API that empowers a wide spectrum of users, including professionals, hospitals, and corporate clinics, to access the insights generated by its advanced algorithms for genetic data interpretation. This innovative approach allows users to delve deeper into the genetic code, offering comprehensive and precise insights into nutrition, fitness, pharmacogenetics, health, and behavioral genetics, ultimately enhancing their ability to serve their clientele.

For instance, biobanks can submit DNA samples for sequencing or simply provide the “RAW” data (large genetic files that usually come in various formats). ADNTRO provides a comprehensive array of findings, including heritage analysis such as Y DNA and X DNA analysis, maternal and paternal haplogroups, and nutritional profiles encompassing factors like lactose intolerance, fructose intolerance, susceptibility to celiac disease, gluten sensitivities, and intricate nuances of vitamins, minerals, and cholesterol metabolism.

ADNTRO also offers personalized dietary recommendations tailored to one's genetic makeup, particularly when weight management is a goal, assessing predisposition to obesity by scrutinizing the well-studied FTO gene.

Beyond nutrition, ADNTRO extends its guidance to the domains of fitness and sports, tailoring recommendations to individual genetic predispositions, such as identifying the most suitable sports and understanding muscle fiber composition. Another critical facet of ADNTRO's services is pharmacogenetics, evaluating the likelihood of adverse reactions to specific drugs or the necessity for dosage adjustments, following the guidelines established by the Consortium for Pharmacogenetics Implementation (CPIC).

ADNTRO meticulously examines genetic markers linked to over 200 complex diseases, providing individuals with insights into their susceptibility or resilience against these conditions. The field of behavioral genetics, encompassing various mental disorders and insights into behavior and personality, receives significant attention.

In the realm of clinical diagnostics, particularly in oncology, ADNTRO excels in diagnosing conditions such as breast cancer and non-cancer-related ailments. These diagnoses rely on comprehensive genetic analyses, including whole exome sequencing and whole genome sequencing, which differ from standard DTC sequencing. The company conducts independent research within the UK Biobank and is on the verge of publishing a groundbreaking study this year on Alzheimer's disease. This study boasts an impressive sensitivity rate of 70 percent, indicating ADNTRO's ability to accurately predict the onset of Alzheimer's after the age of 60 solely through DNA analysis.

However, ADNTRO's innovation doesn't stop at genomics. The company undertakes unique projects, including the creation of digital art inspired by an individual's genome and the concept of a "genetic bonsai," showcasing its creative and pioneering spirit alongside “Conway game of life”, the first ever game based on your genetic sequence and inspired by the work of Jhon Conway, the British mathematician. These pioneering developments underscore ADNTRO's unwavering commitment to pushing the boundaries of genetic exploration.

The ADNTRO core team comprises experts in their respective fields, with Jair Tenorio, Dr. in biomolecular genetics as Chief Scientist Officer, Jorge Blom-Dhal, leading the IT work as the Chief Technology Officer (CTO), Marta Alonso (Dr. in Nutrigenomics) and Sandra Ferreiro as the bioinformatics expert, all of whom play pivotal roles in advancing the company's mission.

In the genomics industry, security and data privacy are of paramount importance due to the sensitive nature of genetic information. ADNTRO has implemented robust measures to safeguard individuals' genetic data. All data is encrypted and stored on European servers in strict compliance with relevant data protection laws. Importantly, the company refrains from conducting family searches to protect the privacy of its customers.

As ADNTRO charts its course into the future of genomics, its sophisticated services firmly position the company as a leader in the field. For professionals and consumers alike, ADNTRO is revolutionizing the exploration and comprehension of genetic makeup.